Dasiglucagon
- Generic Name
- Dasiglucagon
- Brand Names
- Zegalogue
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1544300-84-6
- Unique Ingredient Identifier
- AD4J2O47FQ
- Background
Dasiglucagon is a glucagon analog that acts to increase blood sugar levels. It consists of 29 amino acids similar to endogenous glucagon; however, it contains seven substituted amino acids for improved physical and chemical stability in its drug formulation. In March 2021, the FDA approved dasiglucagon to treat severe hypoglycemia in patients six years and o...
- Indication
Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
- Associated Conditions
- Severe Hypoglycemia
- Associated Therapies
- -
The Bihormonal iLet Bionic Pancreas Feasibility Study
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2019-12-16
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT03840278
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
- Conditions
- Interventions
- First Posted Date
- 2018-12-17
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT03777176
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
🇬🇧Alder Hey Children'sHospital NHS Foundation Trust, Liverpool, United Kingdom
🇺🇸Children's Hospital of Colorado, Aurora, Colorado, United States
Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration
- First Posted Date
- 2018-11-08
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 60
- Registration Number
- NCT03735225
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2021-05-19
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 45
- Registration Number
- NCT03688711
- Locations
- 🇺🇸
Rainier Clinical Research, Inc., Renton, Washington, United States
🇺🇸AMCR Institute, Escondido, California, United States
🇺🇸ProSciento, Inc., Chula Vista, California, United States
Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 42
- Registration Number
- NCT03667053
- Locations
- 🇺🇸
AMCR Institute, Inc, Escondido, California, United States
🇺🇸Indiana University, Department of Pediatrics, Indianapolis, Indiana, United States
🇩🇪Auf der Bult - Diabetes Center for Children, Hannover, Germany
A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT03378635
- Locations
- 🇦🇹
Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇩🇪Profil, Neuss, Germany
🇺🇸ProSciento, Chula Vista, California, United States
A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2017-07-13
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Zealand Pharma
- Target Recruit Count
- 112
- Registration Number
- NCT03216226
- Locations
- 🇨🇦
LMC Calgary, Calgary, Canada
🇦🇹CRC - Clinical Research Center, Medizinische Universität Graz, Graz, Austria
🇩🇪Diabeteszentrum Hamburg West, Gemeinschaftspraxis für Innere Medizin, Hamburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.